PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30031817-6	2018	Intravenous granisetron (1 or 2 mg/kg) produced the dose-dependent suppression of the ongoing and evoked firing of CRD-excited cells within both the CVLM and NTS in normal conditions as well as was able to substantially reduce excitability of the caudal medullary neurons in the presence of colonic inflammation, arguing for the potential efficacy of the 5-HT3 receptor blockade with granisetron against both acute and inflammatory abdominal pain.	Granisetron	12-23	5-hydroxytryptamine receptor 3A	Rattus norvegicus	355-369
31832222-11	2019	Conclusions: This study suggests that granisetron alone could be one treatment option in the management of CINV in patients with non-Hodgkin lymphoma receiving CHOP or R-CHOP regimen.	Granisetron	38-49	DNA damage inducible transcript 3	Homo sapiens	160-164
31832222-11	2019	Conclusions: This study suggests that granisetron alone could be one treatment option in the management of CINV in patients with non-Hodgkin lymphoma receiving CHOP or R-CHOP regimen.	Granisetron	38-49	DNA damage inducible transcript 3	Homo sapiens	170-174
30506577-12	2019	Both treatment with granisetron and genetic knockdown of the 5-HT3A receptor in cells suppressed nuclear factor kappa B (NF-kB) transactivation and phosphorylated p38 (p-p38) accumulation in macrophages.	Granisetron	20-31	5-hydroxytryptamine (serotonin) receptor 3A	Mus musculus	61-67
30506577-12	2019	Both treatment with granisetron and genetic knockdown of the 5-HT3A receptor in cells suppressed nuclear factor kappa B (NF-kB) transactivation and phosphorylated p38 (p-p38) accumulation in macrophages.	Granisetron	20-31	mitogen-activated protein kinase 14	Mus musculus	163-166
30506577-12	2019	Both treatment with granisetron and genetic knockdown of the 5-HT3A receptor in cells suppressed nuclear factor kappa B (NF-kB) transactivation and phosphorylated p38 (p-p38) accumulation in macrophages.	Granisetron	20-31	mitogen-activated protein kinase 14	Mus musculus	170-173
30336258-7	2019	The 5-HT3 receptor (5-HT3R) antagonist granisetron evoked a dose-dependent attenuation of both 5-HT- and T-2 toxin-induced anorectic responses.	Granisetron	39-50	5-hydroxytryptamine (serotonin) receptor 3A	Mus musculus	4-18
30336258-7	2019	The 5-HT3 receptor (5-HT3R) antagonist granisetron evoked a dose-dependent attenuation of both 5-HT- and T-2 toxin-induced anorectic responses.	Granisetron	39-50	5-hydroxytryptamine (serotonin) receptor 3A	Mus musculus	20-26
30336258-7	2019	The 5-HT3 receptor (5-HT3R) antagonist granisetron evoked a dose-dependent attenuation of both 5-HT- and T-2 toxin-induced anorectic responses.	Granisetron	39-50	brachyury 2	Mus musculus	105-108
31832222-0	2019	Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study.	Granisetron	0-11	DNA damage inducible transcript 3	Homo sapiens	88-92
31832222-0	2019	Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study.	Granisetron	0-11	DNA damage inducible transcript 3	Homo sapiens	98-102
31199962-2	2019	Some antiemetic medications (AEM) (droperidol, domperidone, granisetron, metoclopramide and trifluoperazine) used to treat NVP have the unwanted side effect of hERG blockade.	Granisetron	60-71	ETS transcription factor ERG	Homo sapiens	160-164
30950278-0	2019	Highly Variable Expression of CYP1A1 in Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans.	Granisetron	100-111	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	30-36
30950278-9	2019	Together with the high selectivity and especially the high metabolic efficiency of CYP1A1 shown for granisetron and riociguat, it is demonstrated that CYP1A1 plays an important role in the metabolic clearance of these drugs and is responsible for the clinically observed interindividual variability in their pharmacokinetics.	Granisetron	100-111	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	83-89
30950278-9	2019	Together with the high selectivity and especially the high metabolic efficiency of CYP1A1 shown for granisetron and riociguat, it is demonstrated that CYP1A1 plays an important role in the metabolic clearance of these drugs and is responsible for the clinically observed interindividual variability in their pharmacokinetics.	Granisetron	100-111	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	151-157
30797147-1	2019	5-HT3R antagonists such as ondansetron, granisetron and tropisetron have been clinically used to treat nausea and vomiting in chemotherapy patients.	Granisetron	40-51	5-hydroxytryptamine receptor 3A	Homo sapiens	0-6
30551881-5	2019	Granisetron administration reduced pulmonary neutrophil recruitment after CLP.	Granisetron	0-11	hyaluronan and proteoglycan link protein 1	Mus musculus	74-77
30551881-7	2019	Additionally, granisetron could inhibit the activation of p38 MAPK and NLRP3 inflammasome both in vivo and in vitro.	Granisetron	14-25	mitogen-activated protein kinase 14	Mus musculus	58-66
30551881-7	2019	Additionally, granisetron could inhibit the activation of p38 MAPK and NLRP3 inflammasome both in vivo and in vitro.	Granisetron	14-25	NLR family, pyrin domain containing 3	Mus musculus	71-76
30551881-8	2019	Collectively, granisetron protects against sepsis-induced ALI by suppressing macrophage Cxcl1/Cxcl2 expression and neutrophil recruitment in the lung.	Granisetron	14-25	chemokine (C-X-C motif) ligand 1	Mus musculus	88-93
30551881-8	2019	Collectively, granisetron protects against sepsis-induced ALI by suppressing macrophage Cxcl1/Cxcl2 expression and neutrophil recruitment in the lung.	Granisetron	14-25	chemokine (C-X-C motif) ligand 2	Mus musculus	94-99
30359082-6	2019	Alosetron (sc) and granisetron (antagonists) caused a paradoxical increase in the VMR to CRD in SERT-KO female rats.	Granisetron	19-30	solute carrier family 6 member 4	Rattus norvegicus	96-100
31683487-8	2019	In addition, and supported by proteomics analysis, granisetron significantly reduced Abeta induced calcium influx in vitro, and rectified calcium dyshomeostasis in TgSwDI mice brains by restoring calmodulin-dependent protein kinase II/cAMP-response element binding protein pathway, which was associated with cognitive improvement.	Granisetron	51-62	amyloid beta (A4) precursor protein	Mus musculus	85-90
27838796-6	2017	Finally, the activity of antioxidant enzymes (SOD, CAT, and GPx) in the liver improved after cHb and cWb treatment under acute and chronic inflammation.	Granisetron	101-104	catalase	Mus musculus	51-54
29972203-7	2018	The CML-induced serotonin release was reduced by the HTR3 antagonist granisetron.	Granisetron	69-80	5-hydroxytryptamine receptor 3A	Homo sapiens	53-57
28853174-3	2018	Therefore, the objective of our work was to examine the impact of selective 5-HT3 receptor blockade with granisetron on migraine-related nociceptive transmission within the spinal trigeminal nucleus (STN) and the ventroposteromedial nucleus of the thalamus (VPM).	Granisetron	105-116	5-hydroxytryptamine receptor 3A	Rattus norvegicus	76-90
29057666-5	2017	Expert opinion: According to current literature, granisetron 2 mg orally or 0,01mg/kg (1 mg) intravenously per day, co-administered with dexamethasone and NK-1 antagonists is the recommended regime for highly emetogenic chemotherapy.	Granisetron	49-60	tachykinin receptor 1	Homo sapiens	155-159
27838796-6	2017	Finally, the activity of antioxidant enzymes (SOD, CAT, and GPx) in the liver improved after cHb and cWb treatment under acute and chronic inflammation.	Granisetron	101-104	peroxiredoxin 6 pseudogene 2	Mus musculus	60-63
27108935-7	2016	The reverse experiment revealed that granisetron also competitively bound to muscarinic receptors (Ki = 6.5 muM).	Granisetron	37-48	latexin	Homo sapiens	108-111
27809336-4	2016	Granisetron is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP1A1 and CYP3A and is likely a substrate of the ABCB1 transporter.	Granisetron	0-11	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	74-80
27809336-4	2016	Granisetron is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP1A1 and CYP3A and is likely a substrate of the ABCB1 transporter.	Granisetron	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-90
27809336-4	2016	Granisetron is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP1A1 and CYP3A and is likely a substrate of the ABCB1 transporter.	Granisetron	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	124-129
27809336-15	2016	CONCLUSIONS: Polymorphisms in CYP3A5 and CYP1A1 account for some of the variability in systemic clearance and exposure of granisetron in pregnant women.	Granisetron	122-133	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	30-36
27809336-15	2016	CONCLUSIONS: Polymorphisms in CYP3A5 and CYP1A1 account for some of the variability in systemic clearance and exposure of granisetron in pregnant women.	Granisetron	122-133	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	41-47
27392852-10	2016	Only 3 (etodolac, granisetron, and beclomethasone) out of the 5 effective drugs in the bEnd3-based BBB model demonstrated a promising effect to protect the hCMEC/D3-based BBB model integrity.	Granisetron	18-29	BEN domain containing 3	Homo sapiens	87-92
22873819-4	2012	Here we heterologously express mouse 5-HT(3)A receptors in Xenopus oocytes and use unnatural amino acid mutagenesis to establish a cation-pi interaction for both ondansetron and granisetron to tryptophan 183 in the ligand binding pocket.	Granisetron	178-189	5-hydroxytryptamine (serotonin) receptor 3A	Mus musculus	37-45
25960846-9	2015	Also our study showed that controlled CINV episodes in patients who received CMF regimen were better than the regimen including adriamycin (CAF, CHOP) into both granisetron (p=0.06) and metoclopramid (p=0.04).	Granisetron	161-172	DNA damage inducible transcript 3	Homo sapiens	145-149
24813296-6	2014	This effect was abrogated by the 5-HT 3 receptor (5-HT3R) antagonist granisetron, which was luminally delivered to preferentially target vagal terminals.	Granisetron	69-80	5-hydroxytryptamine receptor 3A	Rattus norvegicus	33-48
24813296-6	2014	This effect was abrogated by the 5-HT 3 receptor (5-HT3R) antagonist granisetron, which was luminally delivered to preferentially target vagal terminals.	Granisetron	69-80	5-hydroxytryptamine receptor 3A	Rattus norvegicus	50-56
23338487-0	2013	Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.	Granisetron	16-27	proteasome 26S subunit, non-ATPase 1	Homo sapiens	150-153
23358260-0	2013	Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.	Granisetron	67-78	ATP binding cassette subfamily B member 1	Homo sapiens	15-20
23358260-3	2013	We evaluated the association between the antiemetic efficacy of granisetron plus dexamethasone and ABCB1 polymorphisms 3435C>T and 2677G>T/A.	Granisetron	64-75	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
26576669-10	2016	Selective 5-HT3R antagonists (ondansetron, tropisetron and granisetron) showed positive results on negative symptoms and/or cognitive impairments in phase II trials.	Granisetron	59-70	5-hydroxytryptamine receptor 3A	Homo sapiens	10-16
24718779-8	2014	Further, levels of NK-1R in the cisplatin, thalidomide, and granisetron group were significantly increased at both 5 and 33 h (p < 0.05 vs. control group), with no obvious difference among these three groups.	Granisetron	60-71	tachykinin receptor 1	Rattus norvegicus	19-24
24618127-5	2014	This inhibition was blocked by the 5-HT1A antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY-100635), which was ineffective on its own, whereas the excitation was reversed by granisetron.	Granisetron	223-234	5-hydroxytryptamine receptor 1A	Rattus norvegicus	35-41
22683863-7	2012	We first studied the inhibition of SP-induced Ca(2+) mobilization in NG108-15 cells by palonosetron, ondansetron and granisetron.	Granisetron	117-128	tachykinin 1	Mus musculus	35-37
21737202-8	2011	Sumatriptan, ketanserin, and granisetron treatment attenuated calcium accumulation and 5HT enhancement of capsaicin-evoked CGRP release.	Granisetron	29-40	calcitonin-related polypeptide alpha	Rattus norvegicus	123-127
22209919-7	2012	We report that 5HT pretreatment enhances TRPV1-evoked thermal hyperalgesia, which is attenuated with local pretreatment with ketanserin, granisetron, or sumatriptan.	Granisetron	137-148	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	41-46
19902987-23	2009	An alternative is to use a serotonin agent that is metabolized independently of CYP2D6, such as granisetron, which would obviate the need for genotyping and may lead to an improved drug response.	Granisetron	96-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
21427712-11	2011	The area under the curve, but not peak sensory afferent discharge evoked by IBS samples in rat jejunum, was significantly inhibited by the 5-HT3 receptor antagonist granisetron (P<0.005).	Granisetron	165-176	5-hydroxytryptamine receptor 3A	Rattus norvegicus	139-153
20724042-2	2010	With respect to the many other drugs already in use, such as the first generation 5-HT(3)R antagonist granisetron, palonosetron, a second generation antagonist, clearly demonstrates superior inhibition potency towards the 5-HT(3)Rs.	Granisetron	102-113	5-hydroxytryptamine receptor 3A	Homo sapiens	82-90
20724042-6	2010	The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.	Granisetron	101-112	5-hydroxytryptamine receptor 3A	Homo sapiens	157-165
20154102-7	2010	Granisetron or dexamethasone significantly (p < .05) improved macroscopic and histologic scores, curtailed myeloperoxidase activity and diminished colonic levels of inflammatory cytokines and malondialdehyde.	Granisetron	0-11	myeloperoxidase	Rattus norvegicus	110-125
17182287-11	2007	Intraluminal administration of the 5-HT(3) receptor antagonist granisetron, or the 5-HT(4) receptor antagonist SB 204070 blocked the increase in colonic motility induced by i.c.v.	Granisetron	63-74	5-hydroxytryptamine receptor 3A	Rattus norvegicus	35-51
17679558-1	2007	Granisetron is a selective 5-HT3 receptor antagonist that is used therapeutically for the prevention of vomiting and nausea associated with emetogenic cancer chemotherapy.	Granisetron	0-11	5-hydroxytryptamine receptor 3A	Rattus norvegicus	27-41
16476833-5	2006	CYP2D6 is involved in the metabolism of all of the most commonly available agents, except granisetron, and their efficacy and side effects may therefore be affected by the CYP2D6 polymorphism.	Granisetron	90-101	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
16551910-0	2006	Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.	Granisetron	53-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	95-101
16476833-5	2006	CYP2D6 is involved in the metabolism of all of the most commonly available agents, except granisetron, and their efficacy and side effects may therefore be affected by the CYP2D6 polymorphism.	Granisetron	90-101	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	172-178
15259496-6	2004	Prior administration of granisetron, a 5-HT3 receptor antagonist, inhibited stress-induced changes in defecation in the visceral hypersensitivity group as well as the controls.	Granisetron	24-35	5-hydroxytryptamine receptor 3A	Rattus norvegicus	39-53
16497179-4	2006	This rise in permeability was enhanced 25% by 5-HT (3 x 10(-3) m), reduced by the 5-HT(3)-receptor antagonists granisetron (10(-4)-3 x 10(-4) m) or ondansetron (10(-5)-10(-4) m) or by the 5-HT(4) receptor antagonist SB 203186 (10(-4) m).	Granisetron	111-122	5-hydroxytryptamine receptor 3A	Rattus norvegicus	82-98
16613665-4	2006	Granisetron, a selective antagonist of the 5-hydroxytryptamine3 receptor, also undergoes hepatic metabolism via cytochrome P450 3A4.	Granisetron	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-131
16192915-8	2005	Instead, granisetron is metabolized via the CYP3A4 isoform, which is not subject to significant genetic polymorphism.	Granisetron	9-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50
16192915-10	2005	An alternative is to use a 5-HT3 agent that is metabolized independently of the CYP2D6 isoform, such as granisetron, that would obviate the need for genotyping and may lead to improved prophylaxis of PONV.	Granisetron	104-115	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
16115980-8	2005	Conversely, ondansetron, dolasetron, and granisetron also reversibly inhibited nAChR currents in a dose-dependent manner with IC(50)s of 14.2, 7.8, and 4.4 microM for the adult nAChR and 16.0, 18.6, and 13.9 microM for the embryonic nAChR.	Granisetron	41-52	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	79-84
16115980-8	2005	Conversely, ondansetron, dolasetron, and granisetron also reversibly inhibited nAChR currents in a dose-dependent manner with IC(50)s of 14.2, 7.8, and 4.4 microM for the adult nAChR and 16.0, 18.6, and 13.9 microM for the embryonic nAChR.	Granisetron	41-52	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	177-182
16115980-8	2005	Conversely, ondansetron, dolasetron, and granisetron also reversibly inhibited nAChR currents in a dose-dependent manner with IC(50)s of 14.2, 7.8, and 4.4 microM for the adult nAChR and 16.0, 18.6, and 13.9 microM for the embryonic nAChR.	Granisetron	41-52	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	177-182
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Granisetron	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	114-129
15740177-4	2005	Furthermore, although dolasetron, granisetron, ondansetron and tropisetron are all extensively metabolised by the cytochrome P450 (CYP) system, different components of this system predominate in the metabolism of each of these agents.	Granisetron	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	131-134
12788344-3	2003	This stimulant effect was abolished by pretreatment with the 5-HT(3) receptor antagonist granisetron and was subject to a rapid and pronounced tachyphylaxis, due to desensitization of the peripheric cardiac 5-HT(3) receptor.	Granisetron	89-100	5-hydroxytryptamine receptor 3A	Rattus norvegicus	61-77
14684379-6	2004	Intravenous injection of 5-HT3 receptor antagonist granisetron blocked c-fos expression in all brain nuclei examined, although intracerebroventricular injection of granisetron had no effect, suggesting that 5-HT released from the stomach may activate 5-HT3 receptors located in the peripheral vagal afferent nerve terminals and then induce brain c-fos expression.	Granisetron	51-62	5-hydroxytryptamine receptor 3A	Rattus norvegicus	25-39
14684379-6	2004	Intravenous injection of 5-HT3 receptor antagonist granisetron blocked c-fos expression in all brain nuclei examined, although intracerebroventricular injection of granisetron had no effect, suggesting that 5-HT released from the stomach may activate 5-HT3 receptors located in the peripheral vagal afferent nerve terminals and then induce brain c-fos expression.	Granisetron	51-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-76
14684379-6	2004	Intravenous injection of 5-HT3 receptor antagonist granisetron blocked c-fos expression in all brain nuclei examined, although intracerebroventricular injection of granisetron had no effect, suggesting that 5-HT released from the stomach may activate 5-HT3 receptors located in the peripheral vagal afferent nerve terminals and then induce brain c-fos expression.	Granisetron	51-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	346-351
12943486-6	2003	Granisetron and other 5-HT(3)-receptor antagonists are first-line agents for acute chemotherapy-induced nausea and vomiting (CINV), whereas combination therapy with 5-HT(3)-receptor antagonists, dexamethasone and neurokinin (NK)-1 receptor antagonism (i.e., with the recently approved aprepitant) is an effective approach to prevent delayed CINV.	Granisetron	0-11	tachykinin receptor 1	Homo sapiens	213-239
11819027-5	2002	The paroxetine-induced increase in extracellular dopamine concentration, but not 5-HT concentration, was inhibited by the 5-HT(3)-receptor antagonist granisetron.	Granisetron	150-161	5-hydroxytryptamine receptor 3A	Rattus norvegicus	122-138
12546311-0	2002	Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin"s lymphoma.	Granisetron	35-46	DNA damage inducible transcript 3	Homo sapiens	162-166
12680915-7	2003	Either granisetron (5-HT3 receptor antagonist, 1 micromol L(-1)) or SB204070 (5-HT4 receptor antagonist, 1 micromol L(-1)) in the stimulation chamber significantly decreased IJPs; these decreases were not additive.	Granisetron	7-18	5-hydroxytryptamine receptor 3A	Rattus norvegicus	20-34
15041274-9	2003	When baseline samples were excluded, the correlation remained strong for CWB ENOX times and anti-Xa levels (r=0.84, p<0.001), but was only moderate for NCWB (r=0.73, p<0.001).	Granisetron	73-76	JPX transcript, XIST activator	Homo sapiens	77-81
15041274-11	2003	A CWB ENOX time >/=200 s corresponded to anti-Xa levels >/=0.8 IU/ml in 96% (93/96) of patients.	Granisetron	2-5	JPX transcript, XIST activator	Homo sapiens	6-10
12546311-7	2002	In conclusion, low-dose oral granisetron combined with intravenous dexamethasone had significantly higher protective effects against both acute and delayed nausea and vomiting induced by CHOP-therapy.	Granisetron	29-40	DNA damage inducible transcript 3	Homo sapiens	187-191
12077173-11	2002	The number of APs evoked by ATP was reduced, but not abolished, by the selective 5-HT3 receptor antagonist granisetron (1 microm in the bath).	Granisetron	107-118	ATPase phospholipid transporting 8A2	Homo sapiens	28-31
11742289-0	2001	IgE-mediated allergy to granisetron and safe use of ondansetron.	Granisetron	24-35	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
11833417-3	2001	The Con A- and LPS-stimulated SPR was enhanced in a dose-dependent manner by 5-HT3 receptor antagonist granisetron (GNT) (0.1-0.4 mg/kg, i.p.).	Granisetron	103-114	5-hydroxytryptamine receptor 3A	Rattus norvegicus	77-91
11762972-2	2001	This is particularly relevant with the high-cost 5HT3 antiemetics, which include ondansetron, dolasetron and granisetron.	Granisetron	109-120	5-hydroxytryptamine receptor 3A	Homo sapiens	49-53
9729402-1	1998	The 5-HT3 receptor antagonists, ondansetron, MDL 72222 and granisetron (0.01-1 microM), produced a concentration-dependent increase of K+-evoked [3H]ACh efflux in slices from rat entorhinal cortex preloaded with [3H]choline.	Granisetron	59-70	5-hydroxytryptamine receptor 3A	Rattus norvegicus	4-18
10739360-7	2000	When CDP/ ADM and IFO are delivered on multiple days by CI, granisetron, ondansetron and tropisetron have the same antiemetic efficacy, which declines from the first day onward through successive days.	Granisetron	60-71	adrenomedullin	Homo sapiens	10-21
9884318-10	1999	Because granisetron has been reported to be metabolized primarily by the cytochrome P-450 (CYP) 3A isozyme family in humans, it is possible that cigarette smoke could be an inducer of CYP3A or that CYP1A2, also implicated in the metabolism of granisetron and known to be induced by smoking, is more important in the biotransformation of granisetron than previously thought.	Granisetron	8-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-98
9884318-10	1999	Because granisetron has been reported to be metabolized primarily by the cytochrome P-450 (CYP) 3A isozyme family in humans, it is possible that cigarette smoke could be an inducer of CYP3A or that CYP1A2, also implicated in the metabolism of granisetron and known to be induced by smoking, is more important in the biotransformation of granisetron than previously thought.	Granisetron	8-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	184-189
9884318-10	1999	Because granisetron has been reported to be metabolized primarily by the cytochrome P-450 (CYP) 3A isozyme family in humans, it is possible that cigarette smoke could be an inducer of CYP3A or that CYP1A2, also implicated in the metabolism of granisetron and known to be induced by smoking, is more important in the biotransformation of granisetron than previously thought.	Granisetron	8-19	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	198-204
9884318-10	1999	Because granisetron has been reported to be metabolized primarily by the cytochrome P-450 (CYP) 3A isozyme family in humans, it is possible that cigarette smoke could be an inducer of CYP3A or that CYP1A2, also implicated in the metabolism of granisetron and known to be induced by smoking, is more important in the biotransformation of granisetron than previously thought.	Granisetron	243-254	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-98
9884318-10	1999	Because granisetron has been reported to be metabolized primarily by the cytochrome P-450 (CYP) 3A isozyme family in humans, it is possible that cigarette smoke could be an inducer of CYP3A or that CYP1A2, also implicated in the metabolism of granisetron and known to be induced by smoking, is more important in the biotransformation of granisetron than previously thought.	Granisetron	243-254	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	198-204
9884318-10	1999	Because granisetron has been reported to be metabolized primarily by the cytochrome P-450 (CYP) 3A isozyme family in humans, it is possible that cigarette smoke could be an inducer of CYP3A or that CYP1A2, also implicated in the metabolism of granisetron and known to be induced by smoking, is more important in the biotransformation of granisetron than previously thought.	Granisetron	243-254	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-98
9884318-10	1999	Because granisetron has been reported to be metabolized primarily by the cytochrome P-450 (CYP) 3A isozyme family in humans, it is possible that cigarette smoke could be an inducer of CYP3A or that CYP1A2, also implicated in the metabolism of granisetron and known to be induced by smoking, is more important in the biotransformation of granisetron than previously thought.	Granisetron	243-254	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	198-204
10974317-4	2000	The reduction by CPBG of the NMDA-evoked cardiac response was blocked by prior intra-NTS microinjection of granisetron, a 5-HT(3) receptor antagonist, as well as bicuculline, a GABA(A) receptor antagonist.	Granisetron	107-118	5-hydroxytryptamine receptor 3A	Rattus norvegicus	122-138
9932018-6	1998	At doses of granisetron and devazepide which completely block the response to exogenous 5-HT and CCK, the afferent fibres still responded to both mechanical and chemical stimulation of the mucosa.	Granisetron	12-23	cholecystokinin	Homo sapiens	97-100
9635896-4	1998	This action was markedly attenuated or completely blocked by the selective 5-HT3 receptor antagonists granisetron and BRL 46470A, but not other receptor antagonists.	Granisetron	102-113	5-hydroxytryptamine receptor 3A	Rattus norvegicus	75-89
9593908-2	1998	application of the 5-HT3 receptor antagonist granisetron (0.016-0.16 microg kg-1) and the agonist phenylbiguanide (0.3-3 microg kg-1) on reflex bradycardia evoked by injection of phenylbiguanide (i.v.	Granisetron	45-56	5-hydroxytryptamine receptor 3A	Rattus norvegicus	19-33
8814902-2	1996	The 5-HT3 receptor antagonists ondansetron and granisetron (0.01-10 microM) produced a concentration-dependent increase in both spontaneous and K(+)-evoked [3H]ACh release in the two brain regions studied.	Granisetron	47-58	5-hydroxytryptamine receptor 3A	Rattus norvegicus	4-18
8996183-3	1997	The selective 5-HT3 receptor antagonists GK-128, granisetron, ramosetron, azasetron and ondansetron depressed the increase in fecal pellet output caused by 2-methyl-5-HT and by wrap-restraint stress.	Granisetron	49-60	5-hydroxytryptamine receptor 3A	Rattus norvegicus	14-28
8829149-3	1996	Intrathecal administration of selective 5-HT3 receptor antagonists, granisetron (0.1-100 pmol/rat) and ondansetron (1-1000 pmol/rat), reduced the second phase of the formalin-induced aversive responses without affecting the first one.	Granisetron	68-79	5-hydroxytryptamine receptor 3A	Rattus norvegicus	40-54
9549649-1	1998	This study investigated whether granisetron, a 5-HT3 receptor antagonist, can alter the Bezold-Jarisch reflex (i.e., hypotension and inappropriate heart rate slowing).	Granisetron	32-43	5-hydroxytryptamine receptor 3A	Oryctolagus cuniculus	47-61
9490878-12	1998	5-HT response was completely abolished by the 5-HT3 receptor antagonist, granisetron (0.5 mg kg-1).	Granisetron	73-84	5-hydroxytryptamine receptor 3A	Rattus norvegicus	46-60
9341912-6	1997	1-(3,5-Dichlorophenyl)-3-[(5-methyl-1H-imidazol-4-yl)methyl]imidazoli din-2-one (58), in particular, displayed very high affinity for the 5-HT3 receptor (Ki of 0.038 nM) with a Kb of 5.62 nM in the GPI assay, being more potent than the reference compounds (ondansetron, tropisetron, granisetron, and BRL 46,470) tested.	Granisetron	283-294	5-hydroxytryptamine receptor 3A	Rattus norvegicus	138-152
9313899-8	1997	This study provides evidence that contrary to tropisetron, doses of granisetron able to inhibit the effect of a 5-HT3 receptor agonist failed to reduce that of 5-HT.	Granisetron	68-79	5-hydroxytryptamine receptor 3A	Rattus norvegicus	112-126
9087290-0	1997	[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].	Granisetron	24-35	lysine acetyltransferase 2B	Homo sapiens	48-51
9087290-1	1997	The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated.	Granisetron	27-38	lysine acetyltransferase 2B	Homo sapiens	51-54
9087290-8	1997	The antiemetic efficacy of granisetron decreased significantly by repeated CAF chemotherapy.	Granisetron	27-38	lysine acetyltransferase 2B	Homo sapiens	75-78
8874143-7	1996	However, they are similar to those exhibited by granisetron [endo-1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1 H-indazole-3-carboxamide], a 5-HT3 receptor antagonist.	Granisetron	48-59	5-hydroxytryptamine receptor 3A	Rattus norvegicus	147-161
1966601-1	1990	The 5-HT3 receptor antagonists, ICS205-930, granisetron and zacopride, at low doses, inhibited the hyperactivity caused by a 13 day mesolimbic dopamine infusion in the rat.	Granisetron	44-55	5-hydroxytryptamine receptor 3A	Rattus norvegicus	4-18
8991800-0	1995	Effects of granisetron, a 5-HT3 receptor antagonist, on morphine-induced potentiation of brain stimulation reward.	Granisetron	11-22	5-hydroxytryptamine receptor 3A	Homo sapiens	26-31
7963267-7	1994	IV administration of the 5-HT3 receptor antagonist granisetron (50 micrograms/kg), after bilateral vagotomy had no effect on the response to central vagal stimulation.	Granisetron	51-62	5-hydroxytryptamine receptor 3A	Rattus norvegicus	25-39
7922584-4	1994	The selective 5-HT3 receptor antagonist, granisetron, when applied as a pretreatment completely prevented but did not reverse this action when given after administration of 2-methyl-5-HT while the non-specific 5-HT1,2 receptor antagonist, metergoline, was ineffective.	Granisetron	41-52	5-hydroxytryptamine receptor 3A	Rattus norvegicus	14-28
8507391-2	1993	Systemic administration of the 5-HT1A agonist ipsapirone (1.25-5.0 mg/kg) caused a dose-dependent decrease in ethanol preference and intake, while the 5-HT2 antagonist ritanserin (1.25-5.0 mg/kg) and the 5-HT3 antagonists ondansetron (0.01-1.0 mg/kg) and granisetron (0.5-1.0 mg/kg) failed to alter ethanol consumption.	Granisetron	255-266	5-hydroxytryptamine receptor 1A	Rattus norvegicus	31-37
8496821-2	1993	This compound, as well as ondansetron and granisetron, dose-dependently inhibited the von Bezold-Jarish reflex, a 5-HT3 receptor-mediated response, after intravenous (i.v.)	Granisetron	42-53	5-hydroxytryptamine receptor 3A	Rattus norvegicus	114-128
1682469-1	1991	Studies have been carried out on 7 male adult rats to investigate how the action of the selective 5-HT3 receptor antagonist, granisetron, influences gastrointestinal transit under control conditions and when it is delayed by ileal infusion of lipid.	Granisetron	125-136	5-hydroxytryptamine receptor 3A	Rattus norvegicus	98-112
8556268-8	1995	This release of 5-HT was significantly reduced by granisetron, a selective 5-HT3 receptor antagonist.	Granisetron	50-61	5-hydroxytryptamine receptor 3A	Rattus norvegicus	75-89
7758060-2	1995	On the first day of granisetron treatment, a statistically significant association between complete response and dose was seen (P = 0.001), with the maximum response (81.1%) achieved at a dose of 1 mg BID.	Granisetron	20-31	BH3 interacting domain death agonist	Homo sapiens	201-204
7758060-3	1995	The 24-hour complete response rate with granisetron 1 mg BID was significantly higher than with 0.25 mg BID (61.1%) or 0.5 mg BID (70.2%) (P < 0.009).	Granisetron	40-51	BH3 interacting domain death agonist	Homo sapiens	57-60
7758060-4	1995	The complete response rate for days 0 to 6 was significantly higher with granisetron at 1 mg BID (58.8%) than with 0.25 mg BID (43.7%) or 0.5 mg BID (53.6%) (P < 0.009).	Granisetron	73-84	BH3 interacting domain death agonist	Homo sapiens	93-96
7888294-13	1994	Studies using chemical inhibitors selective for individual P450 enzymes indicated the involvement of cytochrome P450 3A (CYP3A), both pathways of granisetron metabolism being very sensitive to ketoconazole inhibition.	Granisetron	146-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-119
7888294-13	1994	Studies using chemical inhibitors selective for individual P450 enzymes indicated the involvement of cytochrome P450 3A (CYP3A), both pathways of granisetron metabolism being very sensitive to ketoconazole inhibition.	Granisetron	146-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-126
7858893-12	1994	5-HT3 receptor antagonists such as ondansetron, granisetron and tropisetron (0.2 microM) significantly blocked the enhanced K(+)-evoked [3H]-DA efflux from rat olfactory tubercle slices induced by 2-methyl-5HT.	Granisetron	48-59	5-hydroxytryptamine receptor 3A	Rattus norvegicus	0-14
7988637-5	1994	In the presence of the 5-HT3 receptor antagonists, granisetron or ondansetron, 5-HT responses were diminished and exhibited an increased latency to peak.	Granisetron	51-62	5-hydroxytryptamine receptor 3A	Rattus norvegicus	23-37
7919451-1	1994	This review discusses the development and use of 5-hydroxytryptamine3 (5-HT3) antagonists, especially granisetron, for the treatment of chemotherapy-induced emesis.	Granisetron	102-113	5-hydroxytryptamine receptor 3A	Homo sapiens	71-76
7919451-3	1994	Granisetron, a new 5-HT3, is approximately 400 times more potent than metoclopramide and, unlike metoclopramide, does not produce extrapyramidal side effects.	Granisetron	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	19-24
8032707-1	1994	Granisetron, a potent and selective 5-hydroxytryptamine receptor (5-HT3) antagonist was reported to be an effective antiemetic agent both in animal studies and in patients given highly emetogenic chemotherapy.	Granisetron	0-11	5-hydroxytryptamine receptor 3A	Homo sapiens	66-71
8103099-1	1993	Studies were carried out on 20 male adult rats to investigate how the action of the selective 5-HT3-receptor antagonists, granisetron and ondansetron, influence gastrointestinal transit under control conditions and when stomach-to-caecum transit was delayed by ileal infusion of lipid.	Granisetron	122-133	5-hydroxytryptamine receptor 3A	Rattus norvegicus	94-108
1665793-0	1991	The 5-HT3 receptor antagonists LY 277359 and granisetron potentiate the suppressant action of apomorphine on the basal firing rate of ventral tegmental dopamine cells.	Granisetron	45-56	5-hydroxytryptamine receptor 3A	Rattus norvegicus	4-18
1830236-13	1991	5-HT3 receptor antagonists competed for [3H]-quipazine binding with high nanomolar affinities in the three preparations and the rank order of affinity was: (S)-zacopride > quarternized ICS 205-930 2 granisetron > ondansetron > ICS 205-209 (R)-zacopride > quipazine > renzapride > MDL-72222 > butanopride > metoclopramide.	Granisetron	202-213	5-hydroxytryptamine receptor 3A	Rattus norvegicus	0-14
33399295-4	2021	Here, we sought to explore the antidyskinetic efficacy of granisetron, another clinically available 5-HT3 receptor antagonist.	Granisetron	58-69	5-hydroxytryptamine receptor 3A	Rattus norvegicus	100-114
33767348-7	2021	To gain further translational insights, we revealed that combined treatment of zonisamide (enhancing the GABAAR-alpha5 signaling) and granisetron (a selective 5-HT3R antagonist) alleviates mental dysfunction and yields a robust reversal of diet-induced obesity by reducing total calorie intake and altering food preference towards a healthy low-fat diet.	Granisetron	134-145	5-hydroxytryptamine receptor 3A	Homo sapiens	159-165
34663518-9	2021	Furthermore, granisetron administration significantly reduced TNF-alpha, IL-6, HMGB1 and NF-kappaB.	Granisetron	13-24	tumor necrosis factor	Rattus norvegicus	62-71
34663518-9	2021	Furthermore, granisetron administration significantly reduced TNF-alpha, IL-6, HMGB1 and NF-kappaB.	Granisetron	13-24	interleukin 6	Rattus norvegicus	73-77
34663518-9	2021	Furthermore, granisetron administration significantly reduced TNF-alpha, IL-6, HMGB1 and NF-kappaB.	Granisetron	13-24	high mobility group box 1	Rattus norvegicus	79-84
34663518-11	2021	Interestingly, granisetron inhibited pyroptosis as it reduced NLRP3, IL-1beta and caspase-1.	Granisetron	15-26	NLR family, pyrin domain containing 3	Rattus norvegicus	62-67
34663518-11	2021	Interestingly, granisetron inhibited pyroptosis as it reduced NLRP3, IL-1beta and caspase-1.	Granisetron	15-26	interleukin 1 alpha	Rattus norvegicus	69-77
34663518-11	2021	Interestingly, granisetron inhibited pyroptosis as it reduced NLRP3, IL-1beta and caspase-1.	Granisetron	15-26	caspase 1	Rattus norvegicus	82-91
34663518-12	2021	Granisetron was shown to increase Nrf2 and HO-1.	Granisetron	0-11	NFE2 like bZIP transcription factor 2	Rattus norvegicus	34-38
34663518-12	2021	Granisetron was shown to increase Nrf2 and HO-1.	Granisetron	0-11	heme oxygenase 1	Rattus norvegicus	43-47
34208557-5	2021	In HEK293 cells, the inhibition of ASP+ uptake by OCT2 listed in order of potency was palonosetron (IC50: 2.6 muM) > ondansetron > granisetron > tropisetron > dolasetron (IC50: 85.4 muM) and the inhibition of ASP+ uptake by MATE1 in order of potency was ondansetron (IC50: 0.1 muM) > palonosetron = tropisetron > granisetron > dolasetron (IC50: 27.4 muM).	Granisetron	131-142	solute carrier family 22 member 2	Homo sapiens	50-54
34208557-5	2021	In HEK293 cells, the inhibition of ASP+ uptake by OCT2 listed in order of potency was palonosetron (IC50: 2.6 muM) > ondansetron > granisetron > tropisetron > dolasetron (IC50: 85.4 muM) and the inhibition of ASP+ uptake by MATE1 in order of potency was ondansetron (IC50: 0.1 muM) > palonosetron = tropisetron > granisetron > dolasetron (IC50: 27.4 muM).	Granisetron	313-324	solute carrier family 22 member 2	Homo sapiens	50-54
35093429-4	2022	This assay adapted a CYP1A1 selective reaction of granisetron 7-hydroxylation in response to an AhR inducer, 6-formylindolo(3,2-b)carbazole (FICZ), in HepaRG and A549 cell lines.	Granisetron	50-61	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	21-27
35093429-4	2022	This assay adapted a CYP1A1 selective reaction of granisetron 7-hydroxylation in response to an AhR inducer, 6-formylindolo(3,2-b)carbazole (FICZ), in HepaRG and A549 cell lines.	Granisetron	50-61	aryl hydrocarbon receptor	Homo sapiens	96-99
32859502-4	2020	METHODS: In this single-center, prospective, observational, real world study, GTDS plus dexamethasone was administered to MM patients receiving chemo-mobilization based on CY 2 g/m2 plus G-CSF in an outpatient setting.	Granisetron	78-82	colony stimulating factor 3	Homo sapiens	187-192
33152452-2	2021	We have shown, in the hemi-parkinsonian rat model of PD, that the selective serotonin type 3 (5-HT3) receptor antagonists ondansetron and granisetron decreased the severity of established dyskinesia, and ondansetron even attenuated the development of dyskinesia.	Granisetron	138-149	5-hydroxytryptamine receptor 3A	Rattus norvegicus	76-109